ACE inhibitors don’t need to be stopped simply because kidney function is declining. In most cases, continuing them is safer than stopping, even in advanced chronic kidney disease. The decision to pause or discontinue depends on specific thresholds for creatinine rise, potassium levels, and whether the kidney decline is acute or progressive. Understanding these thresholds helps you know what your lab results actually mean and what your care team is watching for.
Why Stopping Isn’t Straightforward
ACE inhibitors lower the pressure inside the kidney’s filtering units, which is protective over the long term but causes a predictable, small dip in kidney function when you first start them. This dip often triggers alarm, but it’s a normal hemodynamic response, not actual kidney damage. The challenge is distinguishing that expected response from a genuine worsening of kidney disease.
A landmark trial published in the New England Journal of Medicine, known as the STOP-ACEi trial, directly tested whether stopping these medications would help patients with advanced, progressive CKD. After three years, kidney function was essentially the same in both groups: an eGFR of about 12.6 in the group that stopped versus 13.3 in the group that continued. Stopping did not improve kidney function, quality of life, or exercise capacity. That result surprised many clinicians who had been reflexively discontinuing the drugs as kidney function worsened.
A large nationwide observational study reinforced those findings with even more striking numbers. Patients who stopped their ACE inhibitor or ARB had a 54.5% five-year mortality rate compared with 40.9% in those who continued. Major cardiovascular events followed a similar pattern: 59.5% versus 47.6%. Stopping did reduce the likelihood of needing dialysis (27.9% versus 36.1%), but the tradeoff was roughly 14 more deaths per 100 patients over five years. For most people, that cardiovascular protection outweighs the kidney-specific risk.
Creatinine Thresholds That Guide Decisions
A creatinine increase of 25% to 30% above your baseline after starting or adjusting an ACE inhibitor is considered acceptable and expected. For example, if your creatinine was 1.2 mg/dL and it rises to about 1.5 mg/dL, that falls within the normal range of response. Your doctor will typically recheck your labs in one to two weeks and, if levels stabilize, continue the medication.
A rise of up to 50% above baseline can still be tolerable, as long as the absolute creatinine value stays below 3 mg/dL or the eGFR doesn’t drop below 25 mL/min. If the increase exceeds 50% but hasn’t hit the hard stop thresholds, the usual approach is to halve the dose rather than discontinue entirely, with close monitoring afterward.
Guidelines point to discontinuation when creatinine doubles from baseline (a 100% increase), or when it exceeds an absolute value of 3.5 mg/dL, or when eGFR falls below 20 mL/min. These are not rigid cutoffs applied in isolation. Your care team weighs them against your cardiovascular risk, the trajectory of your kidney disease, and whether a reversible cause (like dehydration or a new medication interaction) could explain the change.
Potassium Levels and When They Force a Pause
ACE inhibitors reduce the kidney’s ability to excrete potassium, which is why potassium monitoring is routine. A serum potassium level at or above 5.5 mmol/L is the threshold that typically triggers action. At that level, the risk of dangerous heart rhythm problems rises significantly.
The first step is usually dietary potassium restriction and reviewing other medications that raise potassium, such as certain diuretics or anti-inflammatory drugs. If potassium remains elevated despite those adjustments, the ACE inhibitor may need to be reduced or temporarily stopped. Newer potassium-binding medications can sometimes allow patients to stay on their ACE inhibitor by keeping potassium in a safe range, so stopping isn’t always the only option.
Acute Kidney Injury: A Different Situation
Acute kidney injury, where kidney function drops suddenly due to illness, dehydration, surgery, or certain medications, calls for a temporary pause rather than permanent discontinuation. When you’re acutely ill with vomiting, diarrhea, or a serious infection, your blood volume drops and the kidneys become more vulnerable to the blood pressure effects of ACE inhibitors. Many nephrology teams recommend “sick day rules,” meaning you temporarily hold the medication during acute illness and restart once you’ve recovered.
The National Kidney Foundation emphasizes that if your eGFR drops too sharply after starting an ACE inhibitor, your doctor may lower the dose or temporarily stop it while investigating the cause. The key word is “temporarily.” Research involving large populations in England and Sweden found that restarting ACE inhibitors after an acute kidney injury episode, once the patient stabilized, was not associated with harm. In fact, patients who resumed their medication within 30 days of hospital discharge had better long-term outcomes than those who stayed off it permanently.
What a Blood Pressure Drop Tells Your Doctor
Context matters when interpreting a creatinine rise. If your systolic blood pressure dropped by more than 20 mmHg around the same time a new ACE inhibitor was added to a diuretic (water pill), the creatinine increase is likely driven by the combined blood pressure lowering rather than intrinsic kidney damage. In that scenario, the standard approach is to reduce the ACE inhibitor dose or temporarily stop it, then restart at a lower dose once blood pressure and kidney function stabilize. This is a dose-adjustment situation, not a permanent stop.
The Bottom Line on Continuing vs. Stopping
The evidence increasingly favors continuing ACE inhibitors through advancing kidney disease rather than stopping them at a fixed eGFR number. The STOP-ACEi trial showed no kidney benefit from discontinuation, and observational data show a meaningful increase in death and cardiovascular events when these drugs are withdrawn. The specific scenarios that warrant stopping are a creatinine doubling or exceeding 3.5 mg/dL, an eGFR falling below 20, potassium persistently above 5.5 despite management, or an acute illness where blood volume is compromised. Even then, the goal is usually to restart once the acute problem resolves, because the long-term cardiovascular protection these medications provide is substantial.